S. Sutradhar

发表

The Seattle Heart Failure Model: Prediction of Survival in Heart Failure

D. Mozaffarian, P. Poole‐Wilson, S. Anker, 2006, Circulation.

Anand A. Dalal, S. Verma, M. Campone, 2018, Breast Cancer Research and Treatment.

An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®

S. Silverman, J. Kaufman, A. Chines, 2013, Osteoporosis International.

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

Michael E. Lassman, D. Tweedie, X. Chu, 2020, Clinical pharmacology and therapeutics.

The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double‐Blind Trial of Initial Monotherapy vs. Combination Therapy

G. Bakris, J. Fox, A. Lewin, 2004, Journal of clinical hypertension.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial

M. Decramer, F. Sciurba, I. Weisman, 2014, npj Primary Care Respiratory Medicine.

The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.

T. Fuerst, A. Chines, T. Beck, 2015, Bone.

The Use of a Single‐Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo‐Controlled, Multicenter Study

C. Yunis, S. Sutradhar, J. Neutel, 2009, Journal of clinical hypertension.

Prediction of Survival in Heart Failure

D. Mozaffarian, P. Poole‐Wilson, D. Linker, 2006 .

Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers.

K. Dickstein, S. Sutradhar, H. J. Jaatun, 2004, The American journal of cardiology.

TREATMENT STRATEGIES FOR CARDIOVASCULAR RISK FACTOR MANAGEMENT IN PATIENTS WITH HYPERTENSION AND ADDITIONAL RISK FACTORS - EXPERIENCES FROM THE USUAL CARE ARM OF THE CRUCIAL TRIAL: PP.16.90

J. Zamorano, C. Yunis, S. Sutradhar, 2010 .

Comparative Analysis of Multiplex Platforms for Detecting Vitreous Biomarkers in Diabetic Retinopathy

S. Farber-Katz, P. Carrington, S. Sutradhar, 2020, Translational vision science & technology.

Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.

J. Reginster, J. Cappelleri, J. Jansen, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women

J. Reginster, J. Jansen, S. Sutradhar, 2014, Current medical research and opinion.

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm

J. Kanis, S. Sutradhar, A. Svedbom, 2013, Osteoporosis International.

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

S. Sutradhar, I. Chan, K. Schlienger, 2009, Clinical and Vaccine Immunology.

Study of a Refrigerator-Stable Formulation Multicenter Safety and Immunogenicity A Double-Blind , Randomized , Controlled

Chan, S. Sutradhar, R. Z. Rutledge, 2008 .

A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

Ivan S. F. Chan, S. Sutradhar, I. Chan, 2007, Clinical and Vaccine Immunology.

Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (<65 years) and older (≥65 years) patients in the CRUCIAL trial

J. Zamorano, C. Yunis, A. Al-Khadra, 2013, Current medical research and opinion.

245PDDuration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC

P. Ward, F. Esteva, M. Campone, 2017 .

First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.

B. Ramaswamy, K. Blackwell, J. Sparano, 2017 .

S. Verma, M. Campone, H. Burris, 2017 .

19PRibociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden

S. Verma, M. Campone, J. Kattan, 2017 .

Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study.

P. Libby, N. Rifai, S. Nissen, 2012, American heart journal.

Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis

C. Yunis, E. Cho, S. Sutradhar, 2014, Vascular health and risk management.

Proactive Multifactorial Intervention Strategy Reduces the Risk of Cardiovascular Disease Estimated with Region-Specific Risk Assessment Models in Pacific Asian Patients Participating in the CRUCIAL Trial

C. Yunis, E. Cho, S. Sutradhar, 2013, Journal of Korean medical science.

Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial

J. Hradec, J. Zamorano, S. Sutradhar, 2013, Current medical research and opinion.

Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial

J. Zamorano, C. Yunis, S. Sutradhar, 2012, Current medical research and opinion.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

S. Verma, M. Campone, L. Hart, 2017, Breast Cancer Research and Treatment.

Proactive Cardiovascular Risk Management versus Usual Care in Patients with and without Diabetes Mellitus: CRUCIAL Trial Subanalysis

J. Zamorano, A. Al-Khadra, S. Sutradhar, 2012, Postgraduate medicine.

Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial

C. Yunis, A. Al-Khadra, S. Sutradhar, 2011, Current medical research and opinion.

Safety and Quality-Of-Life (QOL) Assessments in the Open-Label, Multicenter, Phase 3b, Expanded Access Study of Everolimus in Patients with Advanced Neuroendocrine Tumors (NET)

T. Hwang, S. Ricci, M. Pavel, 2014 .

A goodness-of-fit test for overdispersed binomial (or multinomial) models

N. Neerchal, J. G. Morel, S. Sutradhar, 2008 .

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

P. Ward, F. Esteva, M. Campone, 2018, Breast Cancer Research and Treatment.

Fertility intentions: are the undecided more like those who want more or want no more children?

S. Becker, S. Sutradhar, 2007, Journal of biosocial science.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK‐rearranged (ALK+) non‐small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND‐1 and ASCEND‐2 trials: 141PD

G. Scagliotti, A. Shaw, T. Mok, 2016, Journal of Thoracic Oncology.

Levels, trends and determinants of child mortality in Matlab, Bangladesh, 1966-1994

N. Alam, R. Bairagi, S. Sutradhar, 1999 .

Understanding Physical Activity In Moderate COPD: Results From A Large, Multicenter Trial

F. Sciurba, I. Weisman, T. Troosters, 2011, ATS 2011.

The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status

R. Rizzoli, A. Chines, S. Adami, 2014, Climacteric : the journal of the International Menopause Society.

Design and Rationale of a Real-Life Study to Compare Treatment Strategies for Cardiovascular Risk Factors: The CRUCIAL Study

C. Yunis, S. Sutradhar, S. Erdine, 2010, Postgraduate medicine.

Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial

M. Malik, R. Grimm, C. Yunis, 2010, Vascular health and risk management.

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2

M. Campone, L. Hart, H. Burris, 2017 .

ON CLASSIFICATION OF A BIVARIATE BINARY OBSERVATION

B. Sutradhar, S. Sutradhar, 2001 .

Design and Rationale of a Real-Life Study to Compare Treatment Strategies for Cardiovascular Risk Factors: The CRUCIAL Study

C. Yunis, S. Sutradhar, S. Erdine, 2010, Postgraduate medicine.

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

M. Campone, H. Burris, J. Beck, 2018 .